Discover
BBLG
Bone Biologics Corporation
0.52
2 x 0.37
2 x 0.71
bid
ask
+
0.02
3.82%
2 @ 04:02 AM
0.50 -0.02 (3.60%)
| Ytd | -64.21% | |
| 1y | -75.75% |
0.50
day range
0.52
0.43
52 week range
2.89
| Open | 0.52 | Prev Close | 0.50 | Low | 0.50 | High | 0.52 | Mkt Cap | 1.43M |
| Vol | 126.74K | Avg Vol | 379.73K | EPS | -0.28 | P/E | N/A | Forward P/E | -0.41 |
| Beta | 0.74 | Short Ratio | 0.18 | Inst. Own | 4.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 0.80 | 200-d Avg | 1.26 | 1yr Est | 16.75 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-14 | 2024-09 | -0.6 | -2.37 | -1.77 | -295.00% |
| 2024-08-09 | 2024-06 | -1.39 | -0.67 | 0.72 | 51.80% |
| 2024-08-09 | 2024-06 | -1.39 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -7.6 | N/A | N/A | N/A |
| 2024-05-14 | 2024-03 | -7.6 | -1.31 | 6.29 | 82.76% |
| 2024-04-04 | 2023-12 | -5.56 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|
Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2023-09-10 | FRELICK JEFFREY | Chief Executive Officer | 17.20K | Purchase |
| 2023-09-12 | WALSH DEINA H | Chief Financial Officer | 15.00K | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | UBS Group AG | 32.85K | 29.57K | 1.32% |
| 2024-09-29 | Morgan Stanley | 28.53K | 25.68K | 1.14% |
| 2024-09-29 | HRT Financial LP | 22.28K | 20.05K | 0.89% |
| 2024-09-29 | Tower Research Capital LLC (TRC) | 1.79K | 1.61K | 0.07% |
| 2024-09-29 | CWM, LLC | 444.00 | 399.00 | 0.02% |
| 2024-09-29 | MFA Wealth Advisors, LLC | 403.00 | 362.00 | 0.02% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-10-30 | Fidelity Extended Market Index Fund | 8.91K | 8.02K | 0.36% |
| 2024-10-30 | Fidelity Total Market Index Fund | 3.94K | 3.54K | 0.16% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 2.75K | 2.47K | 0.11% |
Split
| Split | Date |
|---|---|
| 1 : 6 | 2025-06-10 |
| 1 : 8 | 2023-12-20 |
| 1 : 30 | 2023-06-07 |
| 1 : 2 | 2021-10-13 |
| 1 : 10 | 2018-07-24 |